Monocyte chemotactic protein-1-induced protein-1 (MCPIP1) is a novel multifunctional modulator of inflammatory reactions  by Jura, Jolanta et al.
Biochimica et Biophysica Acta 1823 (2012) 1905–1913
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrReview
Monocyte chemotactic protein-1-induced protein-1 (MCPIP1) is a novel
multifunctional modulator of inﬂammatory reactions
Jolanta Jura, Lukasz Skalniak, Aleksander Koj ⁎
Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30‐387 Krakow, Poland⁎ Corresponding author.
E-mail address: koj@uj.edu.pl (A. Koj).
0167-4889/$ – see front matter © 2012 Elsevier B.V. All
doi:10.1016/j.bbamcr.2012.06.029a b s t r a c ta r t i c l e i n f oArticle history:
Received 20 April 2012
Received in revised form 21 June 2012
Accepted 25 June 2012
Available online 4 July 2012
Keywords:
mRNA stability and decay
RNase
Proinﬂammatory cytokines
NF-kappaB signaling cascade
Ubiquitin-binding domains
DeubiquitinaseThe generalized inﬂammatory response leads to activation of hundreds of genes transcribed in an established se-
quence in specialized cells. Transcriptome analysis of human monocyte-derived cells stimulated with IL-1beta or
with monocyte chemotactic protein-1 (MCP-1) has led to the identiﬁcation of a new inﬂammation-related gene
ZC3H12A encoding a chain of 599 amino acids corresponding to a 66-kDa protein. The protein, given a provisional
name of MCPIP1 (monocyte chemotactic protein-induced protein-1), is expressed in several human and murine
tissues such as bone marrow, spleen, heart and placenta. In in vivo studies, mice with inactivated MCPIP1-
encoding gene showed growth retardation, lymphadenopathy, splenomegaly and enhanced inﬂammatory symp-
toms. Principal molecular features of MCPIP1 include a single zinc ﬁnger motif, an RNase-like PIN domain and
ubiquitin-binding domain. Reports from independent laboratories suggest that MCPIP1 may function also as a
deubiquitinase. Although MCPIP1 is regarded by some authors as a new transcription factor or cell differentiation
factor modulating angiogenesis or adipogenesis, its principal function appears to be downregulation of inﬂamma-
tory responses through at least two independent mechanisms: increased degradation of cytokine mRNAs and in-
hibition of LPS- and IL-1-induced NF-kappaB signaling pathway. The interference with NF-kappaB activation is
highly complex and includes TRAF6 and TANK interaction with the ubiquitin-associated (UBA) domain of
MCPIP1. Puriﬁed MCPIP1 protein was reported to degrade speciﬁc mRNA and cleave K48- and K63-linked poly-
ubiquitin chains. Although some structural features and themechanism of action ofMCPIP1 are not fully explained
yet, its importance in the regulation of inﬂammatory reactions has been ﬁrmly established.
© 2012 Elsevier B.V. All rights reserved.1. Introduction: Principal regulatory mechanisms controlling
inﬂammation
Invasion of pathogens or aseptic tissue injury leads to local inﬂamma-
tion and to a broad systemic reaction known as the acute phase response
(APR) which is an integral part of the innate nonspeciﬁc defense mech-
anism [1–5]. Dinarello [6] distinguishes between autoimmune diseases,
such as rheumatoid arthritis, inﬂammatory bowel disease, type 1 diabe-
tes, or multiple sclerosis that are caused by dysfunction of T-cells with
participation of several cytokines, and autoinﬂammatory diseases, accom-
panying various pathological processes caused by dysfunctional macro-
phages that produce and release an array of cytokines but with a
dominant role of the IL-1 family.
The great variety of stimuli triggering inﬂammation and APR can
be divided into three groups: pathogens (bacterial or viral infections,
invasion of parasites), sterile insults (mechanical or thermal trauma),
and stress of environmental origin (ischemia, local irritants). Besides
the obvious positive effects resulting from inﬂammation, such as
pathogen elimination and restoration of homeostasis, unresolved orrights reserved.untamed inﬂammatory processes can lead to numerous pathological
changes such as host tissue damage. Therefore, strict regulation of
the initiation and termination of inﬂammation is of great importance
and involves numerous stages and components such as speciﬁc re-
ceptors and their antagonists, inhibition of signaling proteins, decay
of transcripts and their products, negative feedback loops, and other
highly complex but poorly understood phenomena that may only be
brieﬂy discussed here.1.1. Initiation of inﬂammation
Pathogen-related inﬂammatory stimuli are recognized by plasma
membrane-associated Toll-like receptors (TLRs) [7–9], or by cytoplas-
mic Nod-like receptors (NLRs) [10,11] [Fig. 1]. These receptors can
discriminate between self and non-self components by recognizing
pathogen-associated molecular patterns (PAMPs) [7] or by detecting
cellular stress- or damage-associated molecular patterns (DAMPs)
[12]. Viral double-stranded RNA, bacterial DNA containing non-
methylated CpG sequences, peptidoglycan components and lipopoly-
saccharides of the bacterial wall, or mannans from the yeast cell wall,
represent typical examples of PAMPs. The pathogen-free noxious stim-
uli of environmental origin are even more diverse and include such
Fig. 1. Principal molecular events in the development of inﬂammatory response. Senti-
nel cells are stimulated by pathogen-associated molecular patterns (PAMPs) recog-
nized by membrane-anchored TLRs or by cytosolic NLRs. This leads to activation of
MAP-kinases (JNK, p38, ERK), activation of NF-κB and other transcription factors
(TFs), and to assembly of inﬂammasomes. Cellular stress- or damage-associated molec-
ular patterns (DAMPs) may give similar effects. Activated transcription factors initiate
synthesis of proinﬂammatory cytokines while processing and secretion of IL-1β take
place in the inﬂammasomes. Released cytokines are recognized by speciﬁc receptors
on target cells and initiate transduction cascades involving several components
(TRAF, IRAK, JAK/STAT) leading to the second wave of activated TFs (NF-κB, AP-1, C/
EBP, STATs). This results in transcription of cytokine-responsive genes and synthesis
of various acute phase proteins. For further detail see text and [101].
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tals of cholesterol (atherosclerosis),ﬁbers of asbestos and grains of silica
(deposited in lungs in asbestosis or silicosis) [12], deposits of denatured
or modiﬁed proteins, such as inactivated alpha-1-proteinase inhibitor
[13] or ﬁbrillar beta-amyloid peptide found in some neurodegenerative
diseases [14]. But cells may be also stimulated by hypo- and hyper-
osmolarity [15,16], hypoxia–reoxygenation [17], accumulation of reac-
tive oxygen species (ROS) [18] and UV radiation [19].
1.2. Inﬂammasomes
Stimulation of TLRs or NLRs triggers a series of events that lead to
the expression of numerous immune and inﬂammation-related
genes, while the cross-talk between these receptors leads to the as-
sembly of multiprotein structures named inﬂammasomes found in
the cytoplasm [10,14]. The inﬂammasome scaffolding is based on
NLRs domain structure and this is reﬂected in the nomenclature.
Among various inﬂammasomes the NLRP3 complex (also known as
NALP3 or cryopyrin) is best characterized [14,20]. It comprises the
NLR protein (from the NOD-like receptor protein family), the adaptor
ASC, and procaspase-1. Usually the multi-step signaling cascade acti-
vated by pathogen-free tissue injury (or by a stress of environmental
origin) merges at some stage with the cascade initiated by pathogens
resulting in the activation of transcription factors, among which the
most important is NF-κB (Fig. 1). This leads to a prompt transcription
of target genes resulting in accumulation of speciﬁc mRNAs coding for
IL-1β and other cytokines.
Macrophages are regarded as typical sentinel cells—they represent
the ﬁrst line of defense and respond promptly to noxious stimuli by
switching on the synthesis of proinﬂammatory cytokines from the
IL-1 and TNF families, and chemokines, such asMCP-1 and IL-8. Howev-
er, some cytokines (IL-1β, IL-18) are produced as inactive precursors
and require proteolytic modiﬁcation by caspase-1 in the inﬂammasome
[3,6,14]. This enzyme is also synthesized as a zymogen, procaspase-1,
whichundergoes autocatalytic processing into two subunits. The gener-
al consensus is thatmaturation and release of IL-1β require two distinct
signals: the ﬁrst leads to synthesis of pro-IL-1β and other components
of the inﬂammasome,whereas the second signal results in the assembly
of the NLRP3 inﬂammasome, caspase-1 activation and IL-1β secretion
[3,11,14]. The assembly of the NLRP3 inﬂammasome can be triggered
by numerous stimuli, chemically and structurally highly different,
some of them listed above as PAMPS and DAMPS. Recent evidence on
the inﬂammasome activation reviewed by Schroeder and Tschopp [14]
emphasizes the role of lysosomal cathepsins and reactive oxygen spe-
cies (ROS), whereas Dinarello [3,6] and others [21] point to the function
of extracellular ATP considered to be a signal of danger. Independently
of the mechanism this leads to the activation of the P2X7 receptor and
subsequent release of intracellular potassium [14] which in turn is a sig-
nal for the inﬂammasomeassembly. Recent discovery showing that viral
NLR homolog inhibits the activity of inﬂammasome [22] may have
therapeutical implications. However, inﬂammasome formation is not
the only way of NF-κB activation, since an important role is played by
protein kinases from the MAP family [23–27], and by reactive oxygen
species generated by such enzymes as lipooxygenase, cyclooxygenase
and the NADPH oxidase complex [28].
1.3. Inﬂammation-related genes and their promoters
Functional genomics analyses indicate that hundreds of genes par-
ticipate in the inﬂammatory response and their coordinated expression
is tightly regulated (for references see [29–31]). These genes can be
grouped into subsets coding for various transcription factors, cytokines,
chemokines, interferons, cellular growth factors and corresponding re-
ceptors, adhesion molecules and enzymes involved in the production
and removal of free radicals, or in modiﬁcation of newly synthesized
polypeptide chains. Despite the diversity of functions of theseinﬂammatory mediators, they share some common features such as
fast decay of their mRNAs and tight control at all stages of transcription
and translation combined with short half-lives of the ﬁnal protein
products [31].
Promoters of genes coding for inﬂammatory mediators usually con-
tain multiple copies of nucleotide sequences binding speciﬁc transcrip-
tion factors (TFs) (reviewed by Koj [32]). The most important is NF-κB
[33] and its activation can be achieved by various signaling cascades
and post-translational modiﬁcations (for more detail see Section 1.5).
Other important TFs include CAAT/Enhancer-Binding Protein (C/EBP,
occurring in seven isoforms) [34], Activator Protein 1 (AP-1, c-Jun/
c-Fos heterodimer [35,36]), Signal Transducer and Activator of
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with ETS domain [39–41], and various TFs recognizing glucocorticoid
or metal response elements (GRE/MRE) [42].
1.4. Factors regulating mRNA stability
In contrast to housekeeping genes, the half-life of mRNAs coding for
cytokines and some other inﬂammation-related molecules is strikingly
short. The structural feature responsible for the fast mRNA decay was
identiﬁed as AU-rich elements, or ARE (the early studies reviewed by
Chen and Shyu [43]). These sequences are recognized by trans-acting
RNA-binding protein factors. Moreover, this interaction manifests as a
whole array of responses, especially taking into account the effect of
MAP kinases on some ARE-binding proteins [44–46]. As we know
today several well deﬁned families of AREBPs participate in the delivery
of ARE-containing mRNAs to the cellular sites of RNA degradation, i.e.
P-bodies and exosomes [47]. The principal AREBPs include:
- AUF family (AU-rich element/poly(U)-binding/degradation factor
1 or 2) [45,48];
- TTP (tristetraprolin), a CCCH zinc-ﬁnger protein which binds to
ARE and destabilizes mRNA [49,50], often with an involvement
of MAP kinases [44,45,51–53]. The principal subject of this review,
the recently discovered MCPIP1 protein with RNase activity, re-
sembles TTP in certain aspects [30,54–56] (see below for details);
- TIA-1 (T cell-restricted intracellular antigen) and TIAR (TIA-related
protein) binds tightly to uridylate-rich sequences found in ARE-
containing mRNA coding for Cox-2 [57];
- KSRP (K-homology splicing regulatory protein) preferably directs
selected mRNA to a multiprotein 3′–5′ exoribonuclease complex
(exosome) [58];
- HuR is amember of the embryonic lethal abnormal vision (ELAV)-like
family of RNA-binding proteins and is able to stabilize, and thus in-
crease half-lives of mRNAs coding for GM-CSF, TNF, IL-3 and COX-2
[45,51,57].
A separate system affecting gene expression through mRNA avail-
ability employs low molecular weight RNA, such as short interfering
RNA (siRNA) or microRNA (miRNA) [59,60] that are generated by a
two-step processing pathway. In the ﬁnal step microRNA precursors
are cleaved by RNase III named Dicer to yield the products composed
of 22–23 nucleotides. These products direct the RNase-induced si-
lencing complex (RISC) to speciﬁc mRNAs containing complementary
sequences thus negatively regulating target gene expression [61]. The
importance of the miRNA system in the regulation of inﬂammatory
reactions is being extensively investigated (see also Section 3).
1.5. Post-translational modiﬁcations of proteins involved in inﬂammation
The synthesis and activity of proteins participating in inﬂammation
are controlled at all stages of transcription and translation, as well as
through post-translational polypeptide chain modiﬁcations, especially
phosphorylation [23,25,44,62], ubiquitination [36,63,64] or limited pro-
teolysis (necessary for activation of pro-IL-1β [3] or activation of
procaspases [65]). Such a precise control at multiple stages is essential
since an excess of proinﬂammatory cytokines may promptly lead to
septic shock, often with a fatal outcome, or to certain chronic diseases,
such as rheumatoid arthritis or Crohn disease [66–69]. Thismay explain
why proteins involved in the inﬂammatory response exhibit as a rule
short half-lives, their removal being usually executed by ubiquitination
followed by degradation in the proteasome (for references see [70]).
The NF-κB family of transcription factors includes ﬁve related pro-
teins: p50, p52, RelA (p65), c-Rel and RelB which act as homo- or
heterodimers (see [71]). Some of them are made functional by limit-
ed proteolysis: p105 to p50, p100 to p52 [72,73], and all are activated
after phosphorylation of the inhibitor IκB by speciﬁc kinase IKK [74].
Kinases, such as mitogen- and stress-activated kinase 1 (MSK1;[75]), casein kinase-II (CSKN-II; [76]) and IKK [77] differentially phos-
phorylate the p65 subunit in response to signaling events. In addition,
many other molecules in the signaling cascade, including receptors
and adaptor proteins, are phosphorylated and the signal is transmit-
ted from the cell membrane to the nucleus.
Ubiquitination and deubiquitination of NF-κB signaling components
are carried out by distinct sets of enzymes [36,78]. Lys48-linked
ubiquitination induced by external stimuli triggers proteosomal degra-
dation of proteins, whereas the released NF-κB is translocated to the
nucleus to control gene expression. Previous studies indicate that
Lys63-linked polyubiquitination of key signaling intermediates (RIP,
TRAF6 and NEMO) is necessary for efﬁcient NF-κB activation [63,70,79].
2. Discovery of MCPIP1/ZC3H12A gene and its biological
signiﬁcance
Cultured blood-derived monocytes/macrophages stimulated with
various pathogens, LPS or some cytokines are known to produce a
plethora of proteins engaged in the inﬂammatory reactions. Using
Affymetrix microarrays and the whole genome approach we found in
human macrophages approximately 300 genes modulated by inﬂam-
matory cytokines IL-1β and/or IL-6, among which 34 may be regarded
as novel cytokine-responsive genes [29]. One of the genes strongly in-
duced by IL-1β (but not by IL-6) appeared to be identical with that cod-
ing for MCPIP1 (monocyte chemotactic protein-induced protein-1)
described previously by Zhou et al. and Liang et al. [80,81]. In a similar
microarray approach those authors found that the expression of the
studied gene was induced not only by IL-1β but also by MCP-1, a
known chemoattractant responsible for the migration of monocytes/
macrophages and involved in the pathogenesis of chronic inﬂammation
[80,82,83].
By searching for nucleotide sequences similar to those coding for
MCPIP1, Liang et al. [81] identiﬁed in the mouse genome a family of
four genes described as Zc3h12a–d (the corresponding genes in
human are denoted ZC3H12A–D). A characteristic structural feature of
this family is the CCCH-type zinc ﬁnger domain. Such structural motifs
are usually involved in RNA binding. The presence of the zinc ﬁnger
domain and a putative nuclear localization signal prompted Zhou et
al. to conclude that MCPIP1 is a new transcription factor responsible
both for angiogenesis [84] and apoptosis of cardiac myocytes [80].
Using overexpression of MCPIP1-GFP fusion protein for microscopy
andmicroarray analysis they found thatMCPIP1 localized in the nucleus
of HEK293 cells. There MCPIP1 induced the expression of apoptotic
genes, contributing to ischemic heart disease [80]. On the other hand,
MCPIP1 was proposed to bind to promoter sequences (EMSA) and di-
rectly activate the transcription of cadherins 12 and 19 to promote an-
giogenesis [84]. However, the latter study has not been conﬁrmed yet.
The idea that MCPIP1 is a transcription factor was challenged by other
authors pointing to enzymatic properties of MCPIP1 behaving as an
RNase [30,54].
Since some clues on the biological role of a protein can be drawn
from its tissue distribution we searched for cell-speciﬁc expression of
MCPIP1 using commercially available membranes loaded with mRNAs
from 12 different human tissues. The highest level of MCPIP1 mRNA
deriving from apparently healthy individuals was detected in leuko-
cytes, a lower one in the heart, placenta and spleen, while the skeletal
muscle, lungs, kidney and liver showed only traces of it [54]. We also
found that the expression of MCPIP1mRNA could be induced by several
cytokines (with a notable exception of IL-6) and in additionwas depen-
dent on the cell type: in human hepatoma HepG2 cells IL-1β was an
effective stimulant, whereas in the promonocytic U937 cell line the
strongest induction was elicited by TNF. On the other hand, Sparna et
al. [85] reported that in primary murine hepatocytes interleukin-17
strongly induces MCPIP1.
In 2010, Liang et al. [36] employed RNA blotting to study the expres-
sion of MCPIP1 in mouse tissues and found the highest mRNA levels in
Fig. 2. Proposed domain organization ofMCPIP1molecule. Numbers indicate approximate
positions of amino acid residues delimiting domains, regions or motifs which have been
appropriately labeled: UBA,Ubiquitin-associated domain (43–89); PRR, Proline-rich region
(100–126 and 458–536); PIN, PilT N-terminus domain (133–270); DUB, deubiquitinating
enzyme domain (133–270); ZF, zinc-ﬁnger motif (305–325); NDR, natively disordered
region (326–457); CCR, C-terminal conserved region (545–598). Ⓟ indicates predicted
phosphorylation sites. Domain borders may vary depending on the source.
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tissues showed the highest MCPIP1 response. Using homologous recom-
bination in embryonic stem cells those authors generated
MCPIP1-negative mice that showed severe splenomegaly, lymphadeno-
pathy, growth retardation and premature death, thus fully conﬁrming
earlier original ﬁndings of Matsushita and co-workers [30]. Moreover,
the mice with the MCPIP1-coding gene knocked out showed also en-
hanced expression of proinﬂammatory cytokines (TNFα, IL-1β, IL-6,
MCP-1) and iNOS [36]. As for the regulation of induced synthesis of
MCPIP1 it was quickly discovered that NF-κB system is involved. Studies
carried out in our laboratory [86] indicate that inhibition of the NF-κB
signaling pathway by super-repressor IκBα S/A resulted in down-
regulation of IL-1β-induced expression of MCPIP1 transcript. Using pro-
moter constructs, EMSA and ChIP assay the IL-1-responsive elements
were located in the second intron of ZC3H12A gene forming an enhancer
comprising four functional NF-κB-binding sites [86]. In search for alter-
native regulatory pathways, Kasza and colleagues [40] demonstrated
that IL-1-dependent MCPIP1 expression may also utilize transcription
factors Elk-1 and SRF.
By the year 2008 it became clear that the product of the ZC3H12A
gene is a single chain of 599 amino acid residues corresponding to the
protein of predicted molecular weight of approximately 66 kDa. In
this molecule one can distinguish a putative nuclear localization signal,
a single zinc ﬁnger (ZF) motif spanning some twenty amino acids
(305–325), and – according to Zhou et al. [80] and Liang et al. [81] –
two proline-rich regions (PRR1 and PRR2) located between residues
100–126 and 458–536 (Fig. 2). However, certain structural and func-
tional features of this protein, such as its intracellular localization,
remained controversial as some authors pointed to the nucleus [80]
while others provided evidence on the presence ofMCPIP1 in cytoplasm
[30,54].
The following functional features of MCPIP1 have been reported
up to date by various authors (for details see Table 1):
- MCPIP1 can be regarded as a new transcription factor participating
on one hand in the development of ischaemic heart disease and
cardiomyocyte apoptosis [80] caused by oxidative stress [87,88],
but on the other also responsible for induction of angiogenesis in
vitro in HUVEC cells [84].
- Another supposition is that MCPIP1 plays a role of a new differen-
tiation factor participating in adipogenesis of 3T3-L1 preadipocytes
[89] occurring without the usual involvement of PPR gamma, but
also taking part in the amyloid precursor protein (APP)-induced
differentiation of neuroprogenitor cells [90], as well as differentia-
tion of precursor cells to osteoclasts with the expression of speciﬁc
markers, a process involving oxidative stress in the endoplasmic
reticulum [91]. Although numerous reports suggest the engage-
ment of MCPIP1 in cell differentiation, each proposing a distinct
mechanism of MCPIP1 action, the whole idea requires experimen-
tal veriﬁcation.
- MCPIP1 is certainly a negative regulator of inﬂammation. In a search
for the mechanisms responsible for these functions of MCPIP1 at
least two separate pathways have been identiﬁed: one utilizing
mRNA decay and the second affecting NF-κB signaling, both leading
to reduced expression of some pro-inﬂammatory mediators [30,54,
55,81]. In the reports mentioned above, MCPIP1 was found to
down-regulate the production of its own inducers: not only IL-1β
[54], but also MCP-1, TNFα [81], and even APP [90]. This can be reg-
arded as a negative feedback loop, in which MCPIP1 attenuates in-
ﬂammatory state by decreasing its fundamental mediators (Figs. 3
and 4).
- Some reports indicate that MCPIP1 acts also as a deubiquitinase re-
moving ubiquitin moieties attached to proteins such as TRAF2,
TRAF3, and TRAF6 [36]. Deubiquitination results in negative regu-
lation of c-Jun N-terminal kinase (JNK) and NF-κB functioning [36]
(Fig. 4).However, we still do not know to what extent the all listed above
antiinﬂammatory functions of MCPIP1 are dependent on its ability to
degrade selected mRNAs.3. MCPIP1 as a novel mRNA decay factor
The ﬁrst convincing evidence of MCPIP1 acting as an RNase was pro-
vided by a group led by Shizuo Akira in their studies on the involvement
of Toll-like receptors in pathogen recognition [2]. When analyzing gene
expression in mouse macrophages they selected 214 genes induced
more than twofold during the ﬁrst 4 h after stimulation with LPS [30].
Hierarchical clustering of these LPS-inducible genes showed that they
may be classiﬁed into three major clusters; genes in cluster 3 were in-
duced through NF-κB signaling in a MyD88-dependent manner. One
gene identiﬁed in this cluster (Zc3h12a) as coding for a protein con-
taining a CCCH-type zinc-ﬁngermotif was extensively studied by several
independent groups of researchers led by S. Akira, P.E. Kolattukudy, S. Fu
and J. Jura [30,54,80,81]. Akira's group [30] extended their studies to
knock-out mice (Zc3h12a−/−). The deﬁcient mice suffered from severe
anemia, had augmented serum immunoglobulin levels, and in response
to TLR ligands showed highly increased production of IL-6 and IL-12p40
(but not TNF). At the same time the IL-6 mRNA decay was slowed
down. In agreementwith the latter effect, overexpression of Zc3h12a ac-
celerated IL-6-mRNA degradation. The authors concluded that the
Zc3h12a protein (i.e. MCPIP1) has a putative amino-terminal ribonucle-
ase domain involved in the control of cytokine mRNA stability. The re-
sults of Matsushita et al. [30] are discrepant from those described by
Zhou et al. [80] but are strongly supported by our conclusions reached
independently [54].
The endonuclease activity responsible for the fast decay of some
mRNAs is usually associated with a characteristic PIN (PilT N-terminus)
domain. Matsushita and co-workers carried out sequence alignment
and predicted a putative PIN domain spanning amino acids 139–297
[30]. Using site-directed mutagenesis they conﬁrmed the importance of
Asp141 (and thus negatively charged enzymatic pocket of PIN domain)
for the degradation of RNA containing the IL-6 3′-UTR. Taking into ac-
count structural features of MCPIP1 based on the nucleotide sequence
we also postulated, and experimentally conﬁrmed, the existence of PIN
domain located between residues 133 and 270 [54].We observed a dras-
tic decrease in the IL-1β transcript levelwhen cellswere transfectedwith
a construct coding for wild-type MCPIP1, but not one expressing a mu-
tant form of this protein devoid of PIN domain [54]. Further evidence
concerning activity of PIN domainwas delivered by Xu et al. [92]. The au-
thors determined high resolution 3D structure of RNase domain of
MCPIP1 by crystallographicmethods. According to these studies the con-
served domain of MCPIP1, spanning amino acids 112–297, is sufﬁcient
for RNase activity in vitro, but other regions such as zinc-ﬁnger domain
and the N-terminal region play an important role in RNA digestion
in vitro and in vivo. Moreover, Xu et al. [92] showed that there is one
Mg2+ ion in the catalytic center of RNase domain, forming an octahe-
dron structure with ﬁve water molecules and Asp226.
Table 1
Biological functions and effects of MCPIP1 related to possible molecular mechanisms.
Year/Ref. no Type of cells/model Conclusions/proposed MCPIP1 function
2006 [80] Cardiac myocytes Transcription factor, regulator of apoptosis
2008 [84] Human umbilical vein endothelial cells (HUVECs) Enhanced angiogenesis; transcription/differentiation factor
2008 [81] Mouse macrophage cell line RAW264.7 Control of macrophage activation; CCCH Zinc ﬁnger domain of MCPIP1involved;
CCCH-zinc ﬁnger protein family
2008 [29] Human monocyte-derived macrophages IL-1β responsive gene identiﬁed as MCPIP1
2009 [90] Glial cells Differentiation factor of glial cells, APP signaling involved
2009 [30] Zc3h12a(−/−) mice; splenic T cells and
macrophages from knock-out mice
RNase degrading speciﬁc mRNAs; control of immune response
2009 [54] Human hepatocellular carcinoma-derived cells
(HepG2), human primary ﬁbroblasts
RNase controlling IL-1β mRNA and its own transcript; AREs independent degradation of
transcripts; gene induced by IL-1β, TNFα, PMA; control of inﬂammatory reactions
2009 [89] 3T3-L1- mouse ﬁbroblast cell line Forced expression of MCPIP1 induces expression of C/EBPbeta, C/EBPdelta, C/EBPalpha,
and PPARgamma and adipogenesis
2009 [86] Human hepatocellular carcinoma-derived
cells (HepG2)
ZC3H12A gene regulated by NF-κB transcription factor; MCPIP1 negatively regulates
NF-κB signaling
2010 [40] Human monocyte-derived macrophages and human
hepatocellular carcinoma-derived cells (HepG2)
Involvement of transcription factors Elk-1 and SRF in MCPIP1 gene regulation
2010 [85] Primary hepatocytes MCPIP1 induced by IL-17 and TNF
2010 [87] Cardiac myoblasts (H9c2) MCPIP1 induction results in sequential events-ROS production, ER stress, autophagy,
and cell death; dysfunction of cardiomyocytes
2010 [96] Human umbilical vein endothelial cells (HUVECs) MCPIP1 as a regulator of cytokine-induced endothelial inﬂammation; regulation of
the adhesion molecule VCAM-1
2010 [36] Zc3h12a(−/−) mice MCPIP1 as deubiquitinase downregulates NF-κB and JNK; control of inﬂammation
2011 [97] Transgenic mice with cardiac-speciﬁc
expression of MCPIP
MCPIP1 decreases LPS-induced myocardial dysfunction; downregulation of NF-κB by IκB
kinase inhibition
2011 [98] Cell lines: RAW 264.7, HeLa, and HEK293; mouse
embryonic ﬁbroblasts and splenocytes from
wild type and Zc3h12a(−/−) mice
Control of response to stress
MCPIP1 inhibits the assembly of stress granules induced by various stressors
2011 [91] Bone marrow cells (BMC) Differentiation of osteoclasts; ER stress and autophagy
2011 [56] Cell lines: HEK293T, HepG2, Jurkat, THP-1 MCPIP1 inhibits microRNA biogenesis via cleavage of the terminal loops of precursor
miRNAs (pre-miRNAs); antagonizes Dicer function; control of gene expression
2011 [99] Fibroblast-like synovial cells (FLS) from rheumatoid
arthritis (RA) patients
Regulation of IL-6 production
Degradation of IL-6-coding mRNA; MCPIP1 knockdown induces activation of STAT3
2011 [100] Primary human microglia and Mouse microglia
from wild type and Zc3h12a(−/−) mice
Neuroinﬂammation and ischemic stroke; absence of MCPIP1 exacerbates ischemic brain
damage by upregulation of proinﬂammatory cytokines; MCPIP1 deﬁciency increases c-Jun
N terminal kinase (JNK) activation
2011 [55] Primary Mouse Embryonic Fibroblasts (MEF)
from wild type and Zc3h12a(−/−) mice
MCPIP1/regnase degrades its own mRNA via a stem-loop region; the protein is degraded
after phosphorylation and polyubiquitination by E3 ligase β-TrCP; control of inﬂammation
2012 [92] 3D structure of PIN domain determined
by crystallography
PIN domain is sufﬁcient for RNase activity; other regions such as zinc-ﬁnger domain and
the N-terminal region play an important role in RNA digestion
Simpliﬁed conclusions are based on principal publications concerning MCPIP and arranged in chronological order.
1909J. Jura et al. / Biochimica et Biophysica Acta 1823 (2012) 1905–1913We also found that MCPIP1 level correlates with the fast degrada-
tion of IL-1β transcript and its own transcript independently of the
presence of AREs. Redundancy of AU-rich sequences in the IL-1β tran-
script turnover was conﬁrmed in our experiments with genetic con-
structs consisting of a minimal promoter and cDNA for luciferase
with or without AREs from the IL-1β transcript [54]. It was speculated
that the region located before AU-rich sequences in the 3′ UTR of the
IL-1β transcript contains a RNA stem-loop motif similar to that foundin IL-6 mRNA essential for destabilization of mRNA and sufﬁcient for
its degradation [93]. Indeed, Iwasaki et al. [55] reported the presence
of such functional structure in the 3′UTR of some cytokine mRNAs,
including that coding for MCPIP1.
As mentioned earlier (see Section 1.4) regulation of mRNA availabil-
ity may involve an alternative route with participation of miRNA. Suzuki
et al. [56] recently reported that MCPIP1 suppresses a broad range of
miRNA activity and biogenesis by cleavage of the terminal loops of
Fig. 3. Reciprocal regulation of IL-1β and MCPIP1 through a feedback loop involving
inhibition of NF-κB and degradation of IL-1β-coding transcript. Binding of IL-1β to
specializedmembrane receptors activates several signal transduction pathways, including
NF-κB transcription factor (1). This leads to stimulation of MCPIP1 synthesis (2), which in
turn down-regulates NF-κB activity (3) [36,81,86]. Finally, MCPIP1 degrades IL-1β-coding
transcript (4) [54], as well as its own transcript, thus decreasing the amount of secreted
IL-1β.
1910 J. Jura et al. / Biochimica et Biophysica Acta 1823 (2012) 1905–1913precursormiRNA. MCPIP1 also carries a vertebrate-speciﬁc oligomeriza-
tion domain important for pre-miRNA recognition. Suzuki et al. point to
the existence of potential antagonism between MCPIP1 and Dicer func-
tion in human cancer. All this indicates that MCPIP1 may have broaderFig. 4. Postulated mechanisms of anti-inﬂammatory activity of MCPIP1. MCPIP1 has multip
MCPIP1 action have been proposed:
(A). Initially MCPIP1 was characterized as a transcription factor responsible for the indu
tricular dysfunction in vivo.
(B). MCPIP1 interferes with signal transmission from the membrane receptors to NF-κB
with an important contribution from protein kinases and enzymes responsible for
(C). At present the most important function of MCPIP1 appears to be endoribonuclease a
way [56].regulatory function than just control biosynthesis of mRNAs coding for
certain cytokines (Fig. 4).4. Involvement of ubiquitination, phosphorylation and proteolysis
in the MCPIP1-dependent downregulation of NF-κB activity
As reported by several authors [31,63,70,78,79,94] reversible
ubiquitination of proteins in the NF-κB signaling cascade appears to
play much more important role than initially anticipated. By using
MCPIP1-deﬁcientmice Liang et al. [36] found thatMCPIP1negatively reg-
ulates IκB and c-Jun N-terminal kinases. The proposedmechanism of this
phenomenon involves deubiquitination of some proteins from the sig-
naling cascade (TRAF2, TRAF6, RIP and NEMO). Further experiments
demonstrated that puriﬁed MCPIP1 can cleave K48- or K63-linked poly-
ubiquitin chain and the responsible protease is blocked by N-ethyl
maleimide, a known inhibitor of cysteine proteinases [36]. The authors
concluded that MCPIP1 has intrinsic deubiquitinating activity which re-
quires both the ubiquitin-associated (UBA) domain located in the
N-terminal conserved region just preceding CCCH ﬁnger, and the Zn ﬁn-
ger itself. Ubiquitinated TRAF2 and TRAF6 components of the NF-κB cas-
cade were suggested as the main substrates for MCPIP1. These results
indicate that the inhibitory effect of MCPIP1 on the inﬂammatory re-
sponse depends, at least partly, on its deubiquitinating potential and
type of the cytokine (IL-1β vs TNF or IL-6) [36].le functions in in vitro and in vivo models (see Table 1). The following mechanisms of
ction of pro-apoptotic genes in cardiac myocytes [80,87] thereby contributing to ven-
and other TFs involved in the expression of genes coding for proinﬂammatory cytokines
protein ubiquitination and deubiquitination [36,55].
ctivity degrading speciﬁc mRNA directly [30,54,55] or by affecting the micro-RNA path-
1911J. Jura et al. / Biochimica et Biophysica Acta 1823 (2012) 1905–1913While our experiments on the role of ubiquitin binding domains in
MCPIP1 were in progress an important paper by Iwasaki et al. was pub-
lished [55]. Those authors introduced the name “regnase-1” for the
MCPIP1 protein to emphasize its regulatory role in the enhanced
mRNA decay, and demonstrated that this protein is phosphorylated by
the IKK complex that leads to its ubiquitination and degradation in the
proteasome. Iwasaki et al. [55] also found that IRAK1 and IRAK2 are as-
sociatedwith phosphorylated regnase-1 and this is critical for regulating
the stability of some cytokine-encoding mRNAs.
Iwasaki and his colleagues [55] observed that IL-6 mRNA was ﬁve-
fold more abundant in macrophages devoid of MCPIP1 and suggested
that expression of Zc3h12a gene is required for suppression of minor
commonly occurring inﬂammatory episodes; when these remain
unchecked an autoimmune disease may easily develop. They de-
scribed [55] speciﬁc albeit not fully understood changes in the level
of MCPIP1 (regnase-1) in macrophages from normal wild-type mice
challenged with LPS: within 15 min most of MCPIP1 protein dis-
appeared but was resynthesized during the next 120 min. The accom-
panying changes in MCPIP1 electrophoretic mobility were explained
as due to phosphorylation by IKKβ. The predicted phosphorylation
site DSGXXS is located in the unstructured region C-terminal to the
nuclease and zinc ﬁnger domains. However, additional experiments
suggest that phosphorylation of regnase-1 depends also on the pres-
ence of IRAK. The authors [55] attempted to solve the discrepancies
by constructing a mathematical model of the control of IL-6 mRNA
by MCPIP1.
Independently Liang and co-workers found that MCPIP1 expression
signiﬁcantly decreased IL-1β induced JNK phosphorylation but had lit-
tle effect on other protein kinases (ERK or p38 and IKKβ) [36]. More-
over, they provided evidence [88] that mechanism of MCPIP1 action
includes induction of oxidative stress in the endoplasmic reticulum
leading to autophagy. This course of events results in the induction of
differentiation of monocytes to osteoclast precursors [91]. This interest-
ing observation further complicates the picture presenting the role of
MCPIP1 in the cell. A similar conclusion was reached by Cifuentes et
al. [95]who analyzedmolecular characteristics and clinical implications
ofMCPIP1. As discussed byAnderson [31]MCPIP1 appears to havemore
than one mechanism of action, can be regulated by proteolysis and
reversible phosphorylation or other post-translational events, and
functions differently in various cell types.
5. Conclusions
This brief review describing the involvement of MCPIP1 in various
regulatory pathways indicates a broad biological role of this protein
which can be regarded either as an executor or a counterbalance of
MCP-1 action. Moreover, MCPIP1 appears to be involved in diverse
types of biological processes such as inﬂammation, differentiation
and apoptosis (for additional references see Cifuentes et al. [95]).
Taking into account the currently available data we conclude that
MCPIP1 is a negative regulator of IL-1-initiated inﬂammation on two
levels (see also Fig. 4):
- at the post-transcriptional stage by degradation of IL-1-mRNA,
and
- at the post-translational stage, by deubiquitination of components
of the NF-κB signaling pathway.
Despite the considerable progress in the elucidation of the struc-
ture/function relationship of MCPIP1 we cannot explain yet the di-
verse dual enzymatic activities of a single MCPIP1 molecule as an
RNase and deubiquitinase; no similar bifunctional hybrid has been
reported so far. Moreover, it is difﬁcult at present to evaluate the
real anti-inﬂammatory potential of MCPIP1 in vivo. Whatever an-
swers to these questions emerge, it is already clear that although
MCPIP1 may be regarded as an enzyme, or an auxiliary protein
from the NF-κB signaling cascade, its role is by no means limited toregulating the decay of some cytokine mRNAs and thus MCPIP1
should be rather treated as a new master switch modulating inﬂam-
matory reactions.Acknowledgements
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